Find Nemonapride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Emonapride, Emilace, [3h]nemonapride, 75272-39-8, (+)-nemonapride, (2r,3r)-nemonapride
Molecular Formula
C21H26ClN3O2
Molecular Weight
387.9  g/mol
InChI Key
KRVOJOCLBAAKSJ-RDTXWAMCSA-N
FDA UNII
Q88T5P3444

Nemonapride
1 2D Structure

Nemonapride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(2R,3R)-1-benzyl-2-methylpyrrolidin-3-yl]-5-chloro-2-methoxy-4-(methylamino)benzamide
2.1.2 InChI
InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)/t14-,18-/m1/s1
2.1.3 InChI Key
KRVOJOCLBAAKSJ-RDTXWAMCSA-N
2.1.4 Canonical SMILES
CC1C(CCN1CC2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3OC)NC)Cl
2.1.5 Isomeric SMILES
C[C@@H]1[C@@H](CCN1CC2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3OC)NC)Cl
2.2 Other Identifiers
2.2.1 UNII
Q88T5P3444
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Cis-n-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide

2. Emonapride

3. Nemonapride, (cis)-isomer

4. Ym 09151-2

5. Ym 09151-m

6. Ym-09151-2

2.3.2 Depositor-Supplied Synonyms

1. Emonapride

2. Emilace

3. [3h]nemonapride

4. 75272-39-8

5. (+)-nemonapride

6. (2r,3r)-nemonapride

7. N-[(2r,3r)-1-benzyl-2-methylpyrrolidin-3-yl]-5-chloro-2-methoxy-4-(methylamino)benzamide

8. Chebi:64219

9. Q88t5p3444

10. N-(cis-1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide

11. 187139-87-3

12. Nemonapride [inn:jan]

13. Ym-09151

14. Unii-q88t5p3444

15. Emilace (tn)

16. Ym-09151-2

17. Nemonapride (jan/inn)

18. Nemonapride [mi]

19. Nemonapride [inn]

20. Nemonapride [jan]

21. (+-)-cis-n-(1-benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-4-(methylamino)-o-anisamide

22. (+-)-cis-n-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide

23. N-(2rs,3rs)-(1-benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide

24. Nemonapride [mart.]

25. Gtpl962

26. Nemonapride [who-dd]

27. Schembl1649724

28. Chembl2261102

29. Dtxsid601116422

30. Zinc538069

31. Bdbm50487259

32. Pdsp1_001527

33. Pdsp2_001511

34. Ncgc00371107-01

35. Benzamide, 5-chloro-2-methoxy-4-(methylamino)-n-((2r,3r)-2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)-, Rel-

36. Benzamide, 5-chloro-2-methoxy-4-(methylamino)-n-(2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)-, Cis-(+-)-

37. Hy-103415

38. B6843

39. Cs-0027847

40. D01468

41. Brd-k47289124-001-02-6

42. (+/-)-cis-n-(1-benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-4-(methylamino)-o-anisamide

43. 5-chloro-2-methoxy-4-(methylamino)-n-[(2r,3r)-2-methyl-1-(phenylmethyl)-3-pyrrolidinyl]benzamide

44. 5-chloro-2-methoxy-4-methylamino-n-[(2r,3r)-2-methyl-1-(phenylmethyl)pyrrolidin-3-yl]benzamide

45. Benzamide, 5-chloro-2-methoxy-4-(methylamino)-n-(2-methyl-1- (phenylmethyl)-3-pyrrolidinyl)-, Cis-(+/-)-

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 387.9 g/mol
Molecular Formula C21H26ClN3O2
XLogP33.9
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count6
Exact Mass387.1713548 g/mol
Monoisotopic Mass387.1713548 g/mol
Topological Polar Surface Area53.6 Ų
Heavy Atom Count27
Formal Charge0
Complexity486
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antipsychotic Agents

Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)


Dopamine Antagonists

Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty